Compare HRTG & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | DBVT |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 769.4M |
| IPO Year | 2014 | N/A |
| Metric | HRTG | DBVT |
|---|---|---|
| Price | $26.29 | $18.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $32.50 | $31.75 |
| AVG Volume (30 Days) | 320.8K | ★ 611.1K |
| Earning Date | 11-05-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.61 | N/A |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $842,277,000.00 | $5,502,000.00 |
| Revenue This Year | $5.45 | $1,768.71 |
| Revenue Next Year | $7.27 | $1,028.88 |
| P/E Ratio | $5.43 | ★ N/A |
| Revenue Growth | ★ 6.12 | N/A |
| 52 Week Low | $9.89 | $3.30 |
| 52 Week High | $31.98 | $26.19 |
| Indicator | HRTG | DBVT |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 51.96 |
| Support Level | $24.87 | $16.49 |
| Resistance Level | $30.20 | $19.62 |
| Average True Range (ATR) | 1.19 | 1.49 |
| MACD | -0.45 | -0.46 |
| Stochastic Oscillator | 24.87 | 18.05 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.